61st American Society of Hematology annual meeting in Orlando, Fla. – Dec. 7-10, 2019

Company Product Description Indication Status
Ascentage Pharma Group International, of Suzhou, China HQP-1351 BCR-ABL inhibitor Tyrosine kinase inhibitor-resistant chronic myeloid leukemia In a phase I study, complete hematologic response rate was 95% in 87 patients in the chronic phase (CP) and 85% in 14 patients in the accelerated phase (AP); major molecular response rate was 37% in CP and 36% in AP
Geron Corp., of Menlo Park, Calif. Imetelstat Telomerase inhibitor Non-del(5q) lower-risk myelodysplastic syndromes Of the 38 evaluable patients from the phase II Imerge study, 42% achieved ≥8-week red blood cell-transfusion independence (RBC-TI) and 28% achieved ≥24-week RBC-TI; median duration of TI was 85.9 weeks
Geron Corp., of Menlo Park, Calif. Imetelstat Telomerase inhibitor Preclinical (myelofibrosis) Treatment of malignant myelofibrosis cells with JAK inhibitor Jakafi (ruxolitinib, Incyte Corp.) followed by imetelstat produced a greater reduction in malignant progenitor and stem cells compared to simultaneous treatment or either drug alone
Humanigen Inc., of Burlingame, Calif. GM-CSF k/o CART19  CAR T with granulocyte-macrophage colony-stimulating factor knocked out Preclinical (acute lymphoblastic leukemia) In a xenograft model for relapsed acute lymphoblastic leukemia, therapy improved overall survival compared to wildtype CART19
Iaso Biotherapeutics Co. Ltd., of Nanjing, China, and Innovent Biologics Inc., of Suzhou, China CT-103A Anti-BCMA CAR T Relapsed/refractory multiple myeloma Objective response rate was 100% in 17 evaluable patients in a phase I study; 70.6% of patients achieved a best response of stringent complete or complete response and 88.2% achieved a best response of very good partial response or better
Medigene AG, of Munich/Martinsried, Germany DC vaccine Dendritic cell vaccine Acute myeloid leukemia 1-year interim assessment of phase I/II trial showed that, upon in vitro stimulation with WT-1 or PRAME, T cells from peripheral blood of 75% (6 of 8) of relapsing patients were capable of producing the pro-inflammatory cytokine IFNgamma, while such a response was detected in only 25% (3 of 12) of the patients in remission

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments